Umbralisib, a Dual PI3Kd/CK1e Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. (2021)
Attributed to:
Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.20.03433
PubMed Identifier: 33683917
Publication URI: http://europepmc.org/abstract/MED/33683917
Type: Journal Article/Review
Volume: 39
Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue: 15
ISSN: 0732-183X